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ABSTRACT
Neurofibromatosis Type 2 (NF2) is a rare genetic disorder, classified as a
neurocutaneous syndrome inherited through an autosomal dominant genetic mutation or
deletion of the NF2 gene in humans. The tumor suppressor gene NF2 encodes the
cytoskeletal protein MERLIN to promote apoptosis and inhibit abnormal cellular
proliferation. Mutations in NF2 lead to a deficiency of functional MERLIN in humans
and can result in hearing loss, disability, and premature death. These symptoms are due to
uncontrollable growth of schwann cells generating bilateral benign tumors
(schwannomas) within the nerve sheath of cranial nerve VIII. Here we seek to understand
the function of MERLIN by studying homologous proteins in zebrafish
(D. rerio). To begin our analysis of MERLIN function, we determined that NF2 has been
duplicated in the zebrafish genome to yield two paralogs, NF2a and NF2b. Compared to
human MERLIN, the proteins encoded by NF2a and NF2b have retained 79% and 72%
amino acid identity, respectively, including high conservation of the signaling “blue box”
motif. Our data also shows that NF2a and NF2b are expressed at different times during
embryonic development, suggesting non-redundant functions. Lastly, we used a
catalytically inactive variant of Cas9 to knock down transcription of nf2a and/or nf2b in
zebrafish. Following knockdown, zebrafish displayed evidence of cellular over
proliferation in hematopoietic cells. Using immunofluorescence, we also observed fewer
apoptotic cells in the brain of knockdown zebrafish when compared to wildtype siblings.
Thus, our data suggests that nf2a and nf2b promotes cell survival in the brain and the
blood island.
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INTRODUCTION
Background
Neurofibromatosis commonly refers to three genetically dominant disorders.
These three disorders are neurofibromatosis 1 (NF1), neurofibromatosis 2 (NF2), and
schwannomatosis. All three present in the clinic as benign peripheral nerve sheath tumors
(PNSTs). While PNSTs are relatively uncommon, making up just 8.6% of all primary
brain and central nervous system tumors reported in 2011–2015, the tumors that arise
from these disorders can result in loss of nerve function and/or neuropathic pain (Brandt
et al., 2019). While the specific genetic variants causing these disorders are well defined,
the molecular mechanisms in which they drive tumorigenesis remain unclear and
represent a key area of research.
Of the three dominant disorders, NF2 is relatively rare (1 in 33,000) and has a
known genetic component caused by mutations in the NF2 gene which encodes the
protein MERLIN. The molecular function of MERLIN and its contribution to
tumorigenesis is not completely understood. Previous studies have shown MERLIN is
a membrane-cytoskeleton scaffolding protein, linking actin filaments to the cell
membrane (Liu, 2020). In this way, MERLIN acts as a tumor suppressor protein and
plays a pivotal role in several other cancers by regulating cell proliferation and cell
migration (Morrow & Shevde, 2012).
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Clinical Description
Neurofibromatosis type 2 (NF2) is characterized by the development of
schwannomas on the vestibular branch of both eighth cranial nerves (Blakeley et al.,
2012). Most NF2 patients develop bilateral vestibular schwannomas that are associated
with other cranial nerves and spinal nerve roots, while some have also attained cranial
and spinal meningiomas and, less frequently, intraspinal ependymomas. Although NF2
causes slow growing tumors that are benign, the disorder diminishes a patient’s quality of
life through effecting hearing, mobility, balance, and possibly causing facial
disfigurement. Depending on the location and quantity of these noncancerous tumors,
NF2 can also lead to early mortality with the average age of death in people diagnosed
with NF2 being 36 years (Blakeley et al., 2012).
Epidemiology
The first case of NF2 was discovered by Wishart in 1822 in which he provided
the first clear description of the disorder of Michael Blair, age 22, that suffered from
tumors of the dura matter, brain, and auditory nerves (Ruggieri et al., 2016). The
prevalence of NF1 is known to affect 1 in every 3,000 people, whereas NF2 affects 1 in
33,000 people worldwide (Nation Institute of Medicine, 2020). Earlier diagnosis and
better survival through improved medical treatments has caused NF2 prevalence to rise
through the established clinical diagnostic criteria as seen in Table 1 (Evans, 2009).
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Table 1: Diagnostic criteria for NF2 based on the National Institute of Health (NIH)
criteria. NF2 can be diagnosed when a pathogenic mutation in the NF2 gene is identified
or when the following criteria are fulfilled.1

Main Criteria

Additional Criteria

Bilateral vestibular schwannomas (VS) or
family history of NF2 plus

Unilateral VS plus any two of the
following: meningioma, glioma,
neurofibroma, schwannoma, posterior
subcapsular lenticular opacities

1) Unilateral VS or

or

2) Any two of the following: meningioma, Multiple meningioma (two or more) plus
glioma, neurofibroma, schwannoma,
unilateral VS or any two of the following:
posterior subcapsular lenticular opacities
glioma, neurofibroma, schwannoma, and
cataract

Etiopathogenesis
The NF2 gene is made up of 17 coding exons that translate to the 595 amino acid cell
membrane-related protein MERLIN. Tumors that arise from the NF2 gene are caused by
the loss of MERLIN in Schwann and meningeal cells. Schwann cells are derived from the
neural crest and produce the myelin sheath around neuronal axons within the peripheral
nervous system (PNS). Schwann cells are responsible for maintaining and regenerating
motor and sensory neurons of the PNS in addition to the cells mainly being required for
myelinating and supplying nutrients to individual axons of the PNS neurons (Manoukian
et al., 2020). The genome of NF2 patients have shown a wide range of mutations in NF2

1

Table 1is referred from Neurofibromatosis type 2 (Nf2): A clinical and molecular review (Evans, 2012)
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frameshift, missense, or splice-site mutations (Evans, 2009). The phenotypes arising from
these genetic mutations are dependent on how the mutation occurred and whether the
protein product retains some functionality, gains a new function, or is completely missing
from the cell. Frameshift mutations are most common and are found to lead to higher risk
of mortality and more severe cases than other mutations (Evans, 2009).
NF2 is caused by a mutation on Chromosome 22 that in approximately half of cases
have been due to inheriting an abnormal NF2 allele from a parent. Two mechanisms exist
in which a patient who is heterozygous for an abnormal NF2 allele can develop NF2.
Firstly, the normal allele may be lost through a loss of heterozygosity (LOH) event later
in development. Second, a de novo mutation of NF2 may occur and take place after
fertilization, resulting in a mosaic expression of two cell lines. Somatic mutations, by
definition, cannot be passed on to offspring. However, somatic mosaicism may prevent
the molecular diagnosis from being established unless tumor tissue is analyzed.
The occurrence of autosomal dominant inheritance of a gain of function NF2 allele
has been found to have an earlier onset age (~18 yrs.) through the maternal gene being
affected while a later onset age (~24 yrs.) through paternal gene being affected (Evans
1998). The expression of mutant NF2 alleles in such cases have been found to be
controlled by endogenous regulatory sequences resulting in a loss of function rather than
a dominant oncogenic effect (McClatchey & Giovannini, 2005).
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Pathology
Schwannomas are benign nerve sheath tumors composed of Schwann cells that
grow around the peripheral nervous system. In NF2, Schwannomas are usually slow
growing and have a predisposition for the superior vestibular branch of the VIII cranial
nerve (Muranen, 2005). Schwannomas are identified as areas of spindle-shaped cells
with intertwining fascicles that may contain blood vessels (Fig. 1a). Schwannomas are
differentiated from sporadic tumors by having a more lobular structure that could only be
sporadically transformed to malignant peripheral nerve sheath tumors after radiation
treatment (McClatchey & Giovannini, 2005).
Another common tumor found in NF2 is meningiomas, which forms on
membranes that cover the spinal cords and brain (Fig. 1b). These tumors originate in the
meninges from arachnoid cap cells and are often slow growing and benign. Meningiomas
that are less than 2 cm in diameter are amongst the more conventional intracranial
tumors. Meningiomas compress brain parenchyma and can invade and distort adjacent
bones, which can lead to subtle symptoms that are easily mistaken for other health
conditions (McClatchey & Giovannini, 2005).
Neurofibroma, ependymomas, and gliomas are additional types of benign tumors
caused by the condition of NF2. Neurofibroma is a small proportion of a nerve related
tumor which is composed of schwann cells, fibroblasts, and mast cells. The tumor mainly
occurs in the skin which causes identifiable soft bumps. Neurofibromas often press
against nerves, as well as grows within them. Ependymomas (Fig. 1c) and gliomas (Fig.
1d) are tumors that originate in the central nervous system and rarely metastasize. The
primary location for these tumors is in the cervical spine and brainstem but may spread
5

throughout the cerebrospinal fluid to other parts of the body. Although neurofibroma,
ependymomas, and gliomas are noncancerous in NF2, malignant progression may still
occur (Gronholm et al., 2005).

Figure 1: MRI images of tumor characterization. T1 weighted MRI without contrast
characterizing (a) schwannoma on the right cerebellopontine angle, arising from the
vestibular nerve branch of the eighth cranial nerve,2 (b) axial sequence of large midline
frontal meningioma with a spoke-wheel pattern,3 (c) ependymoma located in the fourth
ventricle,4 (d) post contrast-enhanced T1-weighted axial of low-grade glioma.5

2

Figure 1a is referred from Department of Radiology of RIPAS Hospital (Bickle, 2012)

3

Figure 1b is referred from MedScape (Islam et al., 2016)

4

Figure 1c is referred from MedScape (Bruce et al., 2018)

5

Figure 1d is referred from Medscape (Jain, 2012)
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Contact Inhibition and Cell Adhesion
Normal cells have the ability to survive and proliferate by the direction of
environmental signals through intercellular and matrix adhesions. Normal cells undergo
growth arrest when in contact with adjacent cells and form intercellular junctions or when
they are detached from the extracellular matrix (McClatchey & Yap, 2012). This process
is known as contact inhibition which is a regulatory mechanism that functions to keep
cells growing into a one cell thick layer. If a cell has plenty of available substrate, it
replicates rapidly and moves freely. This process continues until the cells occupy the
entire space. At this point, normal cells will stop replicating. In contrast, neoplastic cells
evade contact inhibition of proliferation which leads to a disruption of tissue organization
that is a defined event in cancer (Cooper, 2000). Cancer can proliferate and avoid contact
inhibition by cancer cells inhibiting apoptosis within the cell cycle and downregulating
mitogen signaling pathways, regardless of external factors.
Reports have been made that Merlin can control contact-dependent inhibition of
proliferation and that a key consequence of Merlin deficiency is a failure of the cell to
undergo contact-dependent inhibition of proliferation (Muranen et al., 2005). Merlin have
been found to regulate contact-dependent inhibition of proliferation through interaction
with the hyaluronic acid receptor CD44 in some cell types (Cooper & Giancotti, 2014).
Due to the basis of contact-dependent inhibition of proliferation being poorly understood,
the study of Merlin may provide novel insight to better establish that defective cell
communication can contribute to both tumor initiation and metastasis (Evans, 2009). By
doing so, this would provide an explanation for the tumorigenic and metastatic
consequences of Nf2 deficiency in humans.
7

Molecular Pathways
The NF2 tumor suppressor gene encodes the FERM (4.1
protein/Ezrin/Radixin/Moesin) domain protein Merlin. Merlin is composed of a globular
amino-terminal FERM domain followed by an α-helical coiled-coil domain and a
carboxy-terminal domain (Cooper & Giancotti, 2014). The protein Merlin interacts with a
number of proteins that are localized at or underneath the plasma membrane such as with
ERMs and the intracellular domain of CD44. In addition, Merlin interacts with
membrane-associated proteins and regulates the formation of membrane domains.
Merlin's organization of intercellular contacts is essential to normal function in contact
inhibition whereas in Merlin-deficient tissue, Merlin’s organization is disrupted as seen
with Neurofibromatosis Type 2. The importance of Merlin's organization is supported in
Drosophila by the observation that nascent Merlin is recruited to the plasma membrane
(LaJeunesse et al., 1998). NF2 mutations may be caused by a missense mutation that is
thought to occur and be distributed throughout the FERM domain and C-terminal tail of
the MERLIN protein (Pearson et al., 2000). Many questions remain about the precise
mechanism of Merlin and whether Merlin executes multiple independent functions or
controls a specific combination of pathways. By answering these key questions, this will
allow a better understanding of how critical Merlin is in tumor suppression.
ERM Proteins
The ERM proteins (Ezrin/Radixin/Moesin) and the protein Merlin of the NF2
gene are members of the band 4.1 superfamily and are both FERM-containing proteins
(Michie et al., 2019). Although evidence indicates ERM and Merlin are closely related,
their functions differ in that Merlin regulates contact inhibition and is an integral part of
8

cell-cell junctions, while ERM proteins assist in the formation and maintenance of
specialized plasma membrane vesicle structures (Michie et al., 2019). However, Merlin
and the ERM proteins do share similar functions such as linking membrane proteins with
the cortical cytoskeleton and both being involved in numerous signaling pathways with
highly important functions in the PNS and CNS (McClatchey & Fehon, 2009). In
addition, these proteins also share nearly identical tertiary structures, but differentiate in
how Merlin and ERM interacts with other proteins and how they mediate control over
pathways (Michie et al., 2019). The regulation of Merlin and ERM proteins also differ
through ERM proteins being negatively regulated by an intramolecular interaction
between their N and C termini, while Merlin is conformationally regulated (Ramesh
2004). Merlin continues to show differentiation from the ERMs by Merlin going beyond
the linking membranes to the actin cytoskeleton and assembling protein complexes at the
membrane. Merlin also functions at the membrane and in the nucleus while ERM are
mainly restricted to the membranes and the cytoplasm (McClatchey & Fehon, 2009).
What is most interesting about Merlin and this protein's relation to ERM proteins is that
although Merlin is lacking in tumors of NF2 patients, ERM proteins are still expressed
(Ramesh, 2004).
Actin remodeling
A critical aspect of Merlin function is the proteins association with the actin
cytoskeleton. Although Merlin is similar to ERMs, Merlin localizes to specific regions of
cortical actin remodeling, Merlin does not have an actin-binding domain at the C
terminus, but instead may bind actin directly via an N-terminal domain. However,
Merlin’s interaction with the actin cytoskeleton may occur indirectly through the
9

cytoskeletal proteins βII spectrin, paxillin or even the ERM proteins themselves (Evans
2009). Loss of Merlin function has resulted in changes in the morphology of the actin
cytoskeleton similarly to the loss of ERM function leading to dramatic alterations in the
cortical actin cytoskeleton. Although the altered RhoGTPase activity could be an indirect
consequence of these phenotypes, it has been suggested that Merlin may also directly
control actin cytoskeleton remodeling (Kros, 2001). Furthermore, it has been reported
that Merlin and the ERMs can directly interact with and inhibit the function of N-WASP
that normally controls activation of the actin nucleator Arp2/3 which nucleates actin
subunits and drives actin filament branching in specialized cortical domains.

Rac-PAK and mTORC1 Signaling
Through Merlin’s role in binding F-actin and stabilizing actin filaments, it has
been speculated that the protein suppresses mitogenic signaling at the cell cortex to
mediate contact inhibition. Active Merlin is known to suppress Rac-PAK signaling and
restrain activation of the mTORC1 pathway. The p21-activated kinases (PAKs) acts as a
modifier of the cell surface and intracellular signaling cascades that function both in the
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cytoplasm and the nucleus (Brandt et al., 2019). Due to the loss of Merlin, aberrant PAK1
activity has been found in NF2 patients that lead to elevated levels of Rac, which is a
GTP-binding protein that is required for normal cell proliferation and migration. Studies
have suggested that PAK plays a key role in regulating Schwann cells due to loss of PAK
activity in NF2 tumors not reducing two signaling proteins, Erk and Akt, in which were
initially thought to mediate PAK function (Ye &Field 2012).
It has also been reported that the loss of Merlin activates mammalian target of
rapamycin complex 1 (mTORC1) signaling pathway independently of Akt and Erk
signaling in tumor cells (James et al., 2009). NF2 has been identified as a novel negative
regulator responsible for the deregulation of mTORC1, which causes abnormal growth
and proliferation of NF2-linked tumors. Although it is known that NF2 interacts directly
with PAK1 and mTORC1, the molecular mechanism connecting the loss of merlin to
mTORC1 activation, as well as whether PAK is inhibited by Merlin or Merlin is inhibited
by PAK continues to remain unclear. Figure 2 illustrates the complexities of the
intracellular pathway regulated by Merlin.
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Figure 2: Schematic representation of NF2/Merlin. Depiction of major Intracellular
pathways regulated by the protein product of the NF2 gene, Merlin. Growth-Factor and
Membrane-Receptor Signaling. 6

6

Figure 2 is referred from An Update on the CNS Manifestations of Neurofibromatosis Type 2 (Coy et al., 2020)
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Research suggests that Merlin may regulate receptor tyrosine kinase activity and
perhaps trafficking. Merlin has also been reported to interact with several proteins with
established roles in growth-factor receptor signals, in which Merlin can form a ternary
complex with protein dubbed Magicin and Grb2, an adaptor that coordinates receptor
tyrosine kinase and Ras signaling, and with EBP50/NHE-RF1, which can lead to the
interaction with Erbin. Merlin has been also speculated to inhibit EGFR internalization
and signaling upon cell to cell contact (Evans, 2009). Merlin’s role in later stages of
endocytosis suggests the proteins ability to interact with Hepatocyte Growth-Factor
Receptor Substrate (HRS) that controls lysosomal trafficking of membrane receptors. The
localization of Merlin to vesicular structures has been reported to be localized to lipid
rafts, which further supports a role in membrane receptor trafficking. The study of Merlin
could, therefore, provide a novel insight into growth-factor receptor signaling and
trafficking in normal cells, as well as further understanding of growth-factor receptor
deregulation in tumors.

13

MAIN STUDY
NF2 Management
Currently, there is no cure for NF2, and therefore, repeated surgeries and radiation
treatments have been carried out in order to aim to localize tumor control. However, such
tactics have often led patients with damaged nerves and CNS structures to have greatly
diminished NF2 patients’ quality of life. Clinical trials continue to be underway so that
new therapies may be integrated (Blakeley et al., 2012). Of all present-day treatments
available, stereotactic radiosurgery has been the most popular amongst NF2 patients due
to the therapy being able to treat functional abnormalities and small tumors of the brain
with great precision in fewer high-dose treatments than traditional therapies. Symptoms
of the NF2 disorder, such as vision impairment and hearing loss due to the location of the
tumor, have been mitigated through determining NF2 patient candidates for cochlear
nerve implant (CNI) or auditory brainstem implant (ABI) for hearing restoration and
surgery to correct cataracts and retinal abnormalities for vision restoration. Other
complaints of NF2 patients consist of tinnitus, dizziness, facial numbness, balance
problems, and seizures is best managed at a specialty clinic with an initial screening and
annual follow-up evaluations.
Studying NF2 in Zebrafish
Identification of gene homologs and the functional characterization of their
encoded proteins have been identified in many metazoans, including invertebrates, fish,
and birds. Zebrafish (Danio rerio) have long been used for the identification of genes
required for early vertebrate development and have emerged as a model organism for the
study of various cancers (Kimmel, 1989). Zebrafish has been an advantageous model for
14

cancer research as they lack a fully developed immune system during the early larvae
stages. The absence of a matured immune system allows transplantation of tumor cells
without host rejection while also providing investigators the ability to test the effect of
various drugs on tumor growth (Amsterdam et al., 2004). In addition, approximately 70%
of the genes present in humans are represented in the zebrafish genome. Therefore,
genetic manipulation of genes associated with proto-oncogenes or tumor suppressors
have yielded important knowledge toward our understanding of human cancers.
To gain a better understanding of the Merlin protein, the NF2 gene and its role in
Neurofibromatosis 2, we began a systematic study of NF2 homologs in zebrafish. This
project details the identification of 2 merlin paralogs, their temporal expression patterns
and the effects of knocking down these genes during embryonic development.
Specific Aims
The objective of this research is to generate mutant organisms and characterize their
phenotypes associated with silencing the NF2 gene. Specifically, our research focused on
the following aims:
Aim 1: Determine the expression patterns of the NF2 gene in zebrafish to identify
when Merlin is activated.
Approach: Design NF2a and NF2b primers to detect the NF2 gene during the embryonic
stages of zebrafish development through use of Gel Electrophoresis.
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Aim 2: Characterize Merlin’s tumor suppressive function by knocking down
theNF2 gene in zebrafish.
Approach: Design custom oligos for NF2a and NF2b to synthesize gRNA. The gRNA
will be microinjected with dCas9 into zebrafish embryos. At 24 h, antibody stains will be
used to quantify the apoptotic cells within the forebrain through use of the confocal
microscope.
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METHODS
Identification of NF2 Homologs in Zebrafish (D. rerio)
Sequences for the NF2 gene in humans was identified using the ensembl genome
browser (ensembl.org) and compared to transcripts present in the ensembl zebrafish
database to identify 2 paralogs named NF2a and NF2b.
Multisequence Alignment of Human NF2, Nf2a and Nf2b
Amino acid sequences for human NF2, zebrafish NF2a, and zebrafish NF2b were
downloaded and compared using the web-based sequence alignment tool Multialin
(Corpret 1988).
Analysis of Zebrafish Gene Expression in silico
To predict when nf2a and nf2b are expressed, I searched for these genes on the
Expression Atlas housed at the EMBL_EBI (Expression Atlas, 2020). These data were
derived from transcriptomic profiling (RNAseq) of poly-adenylated mRNA expressed in
zebrafish from 1-cell to 5 days post fertilization (White et al., 2017).
Analysis of nf2a and nf2b Gene Expression using RT-PCR
To determine when nf2a and nf2b are expressed, NF2a and NF2b primers were
designed using the online primer design tool, primer3. RNA was extracted and purified
from Zebrafish (D. rerio) embryos raised at 28°C. RNA was collected at the embryonic
stages of blastula 30% epiboly, pharyngula prim-5 (24 h), hatching long-pec (48 h), and
larval protruding-mouth (72 h). Ten embryos were collected from each embryonic stage
and placed in 100ul of Trizol and stored at -20°C. RNA extraction and purification were
performed following the standard protocol provided by Invitrogen and stored in -80°C.
17

(Invitrogen) cDNA was obtained through conducting Real-Time Reverse Transcription
(RT) using QuantiTect Reverse transcriptase Qiagen kit (Qiagen, 2013-2017).
Polymerase chain reaction (PCR) technique was performed using the Thermal Cycler and
Q5 High-Fidelity 2X Master Mix kit (BioLabs inc.). The amplified PCR products were
then analyzed by a 1.5% agarose Electrophoresis Gel using TAE buffer in order to
determine gene expression patterns of NF2a and NF2b.
Knockdown of nf2a and nf2b using Enzyme-dead Cas9 Nuclease
gRNA Synthesis: A custom oligo was designed for NF2a and NF2b and then
compared with the constant oligo to produce 117 base pairs. An annealing and an
extending reaction were then conducted using the thermal cycler. DNA was obtained and
purified using IBI- Gel/PCR DNA Fragments Extraction Kit and then run on a 2%
agarose gel to verify product obtained. Using mMESSAGE mMACHINE T7
Transcription Kit, an In Vitro Transcription reaction was conducted and then incubated at
37℃ overnight. gRNA was then purified, pelleted and then run on a 2% agarose gel to
verify product obtained.
Microinjection of gRNA and mRNA encoding dCas9 (catalytically inactive
dCas9, a generous gift from Didier Stanier, University of Cologne, Germany) (Rossi et
al., 2015). The gRNA was then microinjected along with mRNA encoding dCas9 into the
yolk of the embryos during the one to two cell stage. Embryos were incubated at 28℃ for
24 hours post fertilization (h), dechorionated, and then stored in 4% PFA overnight.
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Antibody Staining for Caspase-3 to Label Apoptotic Cells
The 4% PFA was later replaced with methanol to permeabilize the cells. PBST
(Phosphate buffered saline with Tween-20) and PDT (Phosphate buffered saline with
DSMO and Trition X) were used to conduct washes prior and post addition of Alpha
Tubulin, DAPI, and Rabbit Anti-active Caspase along with their conjugated antibodies. A
blocking buffer was used to prevent nonspecific binding of the membrane. The 24 h
embryos were then analyzed using the confocal microscope to measure the apoptotic cells
within the forebrain.
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Figure 3: Amplified and duplicated segments of DNA Template with NF2a, NF2b,
and β-Actin primers. Forward and Reverse Primers of NF2a and NF2b were designed to
create copies of targeted DNA sequence.
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RESULTS
Comparison of Human and Zebrafish NF2 Homologs
The zebrafish genome encodes two homologs of NF2/Merlin, named Nf2a and
Nf2b. A comparison of the amino acid sequences of human and zebrafish Merlin show
that the gene is highly conserved being 46% similar to Human (Shabardina et al., 2019).
A closer look at the amino acid sequence also shows that the Zebrafish paralogs maintain
the highly conserved “blue box” motif (174-YQMTxxMWEE-194) known to be required
for NF2 signaling. Suggesting that these proteins may retain a similar function to human
Merlin.

Figure 4: Comparison of NF2 in Humans to Nf2a and Nf2b in Zebrafish. Red amino
acids are identical, blue are similar, and black are non-conserved residues. The percent
identity of Zebrafish NF2a and the Human NF2 gene is 79%. The percent identity of
Zebrafish NF2b and the Human NF2 gene is 71%.7

7

Figure 4 is referred from Multiple Sequence Alignment with Hierarchical Clustering (Corpet, 2000)
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NF2a and NF2b have Different Temporal Expression Patterns as Predicted in silico
To begin the study of NF2 in zebrafish, we wanted to know when the gene is
expressed during embryonic development. To do this, we found a publicly available
database that allowed me to browse all the mRNAs sequenced (RNAseq) in zebrafish at
different stages of embryonic development. A search for nf2a showed that the gene was
expressed from the zygotic (1-cell) stage through the gastrula 50% epiboly stage and then
no longer expressed from the gastrula 75% epiboly stage through 5 dpf. nf2b, on the other
hand, showed no expression during the zygotic stage, but then showed expression from
the cleavage 2-cell stage through 5 dpf.

Figure 5: In-silico gene expression analysis of nf2a and nf2b through the first 5 days
of development. Reverse-transcription PCR of Nf2a and Nf2b conflict with predicted
expression patterns.8

8

Figure 5 is referred from Expression Atlas (2020)
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To verify these results we obtained in silico, we designed NF2a and NF2b primers
for reverse-transcription PCR and extracted RNA from four different embryonic stages of
development. Our results disagreed with the predicted expression as indicated NF2a was
not expressed during 30% epiboly and 1 dpf, but then was expressed during 2 dpf and 5
dpf. The results for NF2b indicated expression during 30% epiboly, no expression during
1 dpf, and then expression during 2 dpf and 5 dpf. We concluded from these results that
nf2a is not expressed in the oocytes and that the development of NF2a is under exclusive
control of the zygotic genome starting before 2 dpf, but not before 24 h. We have also
determined that nf2b is expressed at 30% epiboly, turns off during the transitions at 1 dpf
when the maternal transcripts are cleared. It once again turns on at 2 dpf and 5 dpf when
the zygotic genome itself gives rise to nf2b. The identified NF2a and NF2b gene
expression patterns differed from the in-silico gene expression analysis reported in
Zebrafish development seen in Figure 4. Data obtained indicated that NF2a is expressed
at the hatching long-pec stage (48 h) and larval protruding-mouth stage (72 h), while in
silico showed that zebrafish in these embryonic stages had little to no expression (Fig. 5).
Furthermore, NF2a obtained at blastula 30% epiboly (4.66 h) did not show gene
expression, where in silico did show gene expression at blastula dome (4.33 h) and
blastula 50% epiboly (5.25 h) (Fig. 5 & 6). No expression of NF2 at the pharyngula prim5 stage (24 h) of development was found, which corresponded with the in-silico gene
expression analysis reported (Fig. 5 & 6).

23

Figure 6: NF2 Gene Expression Pattern. 1.5% Agarose gel electrophoresis analysis of
DNA of NF2 gene and β-Actin obtain from PCR products. 1.0-10.0kb of DNA ladder,
Lane 1 is blastula 30% epiboly/ 4.66 h, Lane 2 is pharyngula prim-5/ 24 h, Lane 3 is
hatching long-pec/ 48 h, and Lane 4 is larval protruding mouth/ 72 h. First column is
NF2a, second column is NF2b, third column is the positive control/ β-Actin.
Knockdown of nf2a and nf2b Causes Excessive Proliferation of Hematopoietic Cells
in Zebrafish ‘Blood Islands’
To better understand the function of nf2a and nf2b we used a modified protocol of
CRISPR/Cas9 to knockdown nf2a and nf2b. Following knockdown, we observed 24 h
zebrafish at 40X through use of the stereo microscope. Our results indicated that
microinjecting gRNA and mRNA encoding an enzyme-dead Cas9 nuclease
transcriptionally repressed Merlin1a and Merlin1b that lead to diverse morphological
phenotypes including increased cellular proliferation in the posterior blood island,
bulging “tumors” in the notochord, in addition to gene expression patterns of NF2a and
NF2b being observed, phenotypes of dCas9 injected nf2a and nf2b were also identified at
24 h (Fig. 6). Abnormalities detected in nf2a injected (Fig. 6B & C) in comparison to
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uninjected zebrafish embryo (Fig. 6A), included severe curvature of the notochord and
increased cellular proliferation in the posterior blood island. For Figure 6B, potential
tumors on caudal fin were also identified. While injected nf2a embryos had more severe
phenotypes, nf2b injected embryos had more moderate curvature of the notochord. These
data suggest that Nf2a and Nf2b may be important for inhibiting excessive proliferation
in these hematopoetic cells.

Figure 7: Cellular proliferation in the posterior blood island at 24 h embryos
produced by microinjections of nf2a and nf2b. Severe curvature phenotype of the
notochord in nf2a injected (B and C) and moderate curvature phenotype of the notochord
in nf2b injected (D) are shown relative to an uninjected control embryo (A).
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To further identify probable cause of phenotypes identified (Fig. 7), apoptotic cells
of 84 zebrafish embryos at 24 h were observed and counted through use of the confocal
microscope (Fig 8). Apoptotic cells were observed in the forebrain and compared to
control, nf2a injected, and nf2b injected through use of ANOVA (Fig. 9). The ANOVA
model indicated a significant difference for microinjected embryos at 24 h with nf2a and/or
nf2b showing less apoptotic cells than control.
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Figure 8: Confocal microscopy analysis of apoptosis in zebrafish forebrain at 24 h.
Arrowheads indicate apoptotic cells.
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Figure 9: ANOVA model of Apoptotic cells in the forebrain. Apoptotic cells in the
forebrain at 24 h in comparison to the uninjected control embryos. ANOVA model
indicates significant difference for microinjected embryos at 24 h (p<0.001).
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DISCUSSION

A deficiency of Merlin leads to the NF2 genetic disorder that can result in hearing
loss, disability, and premature death because of uncontrollable growth of benign tumors
within the nervous system. Although surgeries reduce tumor mass have been the most
sought out treatment for managing NF2, these therapeutic techniques do not eradicate the
full effects of NF2, nor provide a long-term cure. The tumor suppressor gene NF2 is
known to prevent abnormal cell division through encoding MERLIN to promote
apoptosis and preventing cellular proliferation. Through our research we have determined
that NF2a is not expressed in the zebrafish oocytes and that the development of NF2a is
under exclusive control of the zygotic genome starting before hatching long-pec/48 h, but
not before pharyngula prim-5/24 h (Fig. 6). We have also determined that NF2b is
expressed at blastula 30% epiboly/ 4.66 h, turns off during the transitions at 1dpf when
the maternal transcripts are cleared (Fig. 6). It once again turns on at hatching longpec/48 h and larval protruding-mouth/72 h when the zygotic genome itself gives rise to
NF2b (Fig. 6). Using publicly available dataset, in silico, we found that nf2a is maternally
deposited and highly expressed through the first 6 h of development, while nf2b is
expressed immediately after fertilization and maintained through 5 days of development
(Fig. 4).
Genetic knockdowns of nf2a and nf2b led to varying morphological phenotypes
including substantial proliferation of hematopoietic cells in 24 h zebrafish (Fig. 7).
Researchers backcrossed generations of C57/B6 background crossed with C57B6 Mx1
Cre transgenic mice and found that NF2 knockout mice may exhibit two distinct
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phenotypes affecting hematopoietic cells (Larsson 2008). This research supports NF2’s
crucial role in regulating stem cells within the hematopoietic compartment.
Apoptotic cells were observed in the forebrain of zebrafish at 24 h (Fig. 8). The
statistical analysis that was used for quantification of apoptotic cells was the ANOVA
model. ANOVA demonstrated statistical significance for microinjected embryos at 24 h
with nf2a and/or nf2b indicating a decrease in the amount of apoptosis localized within
the forebrain of zebrafish (Fig. 9). Previous research has shown that inhibiting
endogenous NF2 by siRNA knockdown rescued INS-1E cells from high glucose- and
high-glucose/palmitate-induced apoptosis, as demonstrated by decreased caspase-3 levels
(Yuan et al., 2016). Therefore, by silencing NF2 β-cells were protected from highglucose/palmitate-induced apoptosis in isolated human islets (Yuan et al., 2016).
Phenotypic characteristics of NF2 have been well documented in the literature. In
zebrafish l, the phenotypic characteristics included curvature of the notochord, increase
of cell proliferation in the blood islands, and bulging “tumors” in the notochord (Fig. 7).
With our results we noticed a significant discrepancy between nf2a and nf2b phenotypic
characteristics. The characteristics of nf2a were seen as more severe as opposed to nf2b.
We postulate that the reason behind the discrepancy we see between nf2a and nf2b is
that, nf2a is expressed earlier on in the embryological development stages of zebrafish
which can induce more severe phenotypes given the fact that early on in the
embryological development important structures are being created.
We hope to further our research by pinpointing exactly when NF2a and NF2b are
expressed during embryological stages of zebrafish development along with quantifying
absolute levels of RNA transcripts based on quantitative analysis. Our future aspiration
30

also includes conducting a whole-mount in situ hybridization to determine where
NF2a/NF2b are expressed and generating nf2a and nf2b knockdown lines to assess the
effects of lifelong loss of the NF2 gene in zebrafish. Our long-term goal is to establish a
zebrafish model of Neurofibromatosis Type 2 so that we may further our understanding
of the protein merlin that will lead to a potentially better alternative cure to reduce
tumorigenesis and prevent the escalation of NF2-related tumors.
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